Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer.

Cancer Research
Valerie N BartonJennifer K Richer

Abstract

Preclinical and early clinical trials indicate that up to 50% of triple-negative breast cancers (TNBC) express androgen receptor (AR) and are potentially responsive to antiandrogens. However, the function of AR in TNBC and the mechanisms by which AR-targeted therapy reduces tumor burden are largely unknown. We hypothesized that AR maintains a cancer stem cell (CSC)-like tumor-initiating population and serves as an antiapoptotic factor, facilitating anchorage independence and metastasis. AR levels increased in TNBC cells grown in forced suspension culture compared with those in attached conditions, and cells that expressed AR resisted detachment-induced apoptosis. Culturing TNBC cells in suspension increased the CSC-like population, an effect reversed by AR inhibition. Pretreatment with enzalutamide (Enza) decreased the tumor-initiating capacity of TNBC cells and reduced tumor volume and viability when administered simultaneously or subsequent to the chemotherapeutic paclitaxel; simultaneous treatment more effectively suppressed tumor recurrence. Overall, our findings suggest that AR-targeted therapies may enhance the efficacy of chemotherapy even in TNBCs with low AR expression by targeting a CSC-like cell population with ancho...Continue Reading

References

Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Apr 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kathryn B HorwitzCarol A Sartorius
May 1, 2008·Journal of the National Cancer Institute·Xiaoxian LiJenny C Chang
Apr 13, 2010·Nature·Marie-Liesse Asselin-LabatJane E Visvader
Sep 3, 2010·Virchows Archiv : an International Journal of Pathology·Donata MicelloFausto Sessa
May 10, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Laura C CollinsRulla M Tamimi
Jun 3, 2011·The Journal of Clinical Investigation·Lauren L C MarottaKornelia Polyak
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 28, 2011·The EMBO Journal·Jessica L L RobinsonJason S Carroll
Oct 4, 2012·Acta histochemica·Ivana MrklićSnježana Tomić
Feb 9, 2013·The Journal of Clinical Investigation·Neil E BholaCarlos L Arteaga
Aug 10, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Aye Aye ThikePuay Hoon Tan
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko MasudaNaoto T Ueno
Aug 24, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ayca GucalpUNKNOWN Translational Breast Cancer Research Consortium (TBCRC 011)
Nov 19, 2013·Endocrine-related Cancer·Zongjing ZhangMingzhao Xing

❮ Previous
Next ❯

Citations

Nov 4, 2017·International Journal of Molecular Sciences·Nalo HamiltonRichard Pietras
Mar 2, 2019·Critical Reviews in Clinical Laboratory Sciences·Stella K Vasiliou, Eleftherios P Diamandis
Feb 20, 2020·JCO Global Oncology·Geetanjali SainiRitu Aneja
Oct 31, 2019·BMC Cancer·Toru HanamuraKen-Ichi Ito
Oct 17, 2019·World Journal of Stem Cells·Pia GiovannelliGabriella Castoria
Sep 29, 2020·Frontiers in Endocrinology·Mengyao ChenFuming Qiu
Mar 9, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carmela RicciardelliWayne D Tilley
Nov 21, 2020·Breast Cancer Research : BCR·Shristi BhattaraiRitu Aneja
Feb 17, 2021·Signal Transduction and Targeted Therapy·He-Ming ZhouQin Li
Feb 8, 2021·Endocrinology·Maddison Archer, Natasha Kyprianou
Oct 17, 2020·NPJ Breast Cancer·Anna R MichmerhuizenCorey W Speers
Jul 17, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Runtian WangXiaoxiang Guan
Jul 10, 2021·Molecular and Cellular Endocrinology·Yurong Zheng, Antoine E Karnoub
Nov 6, 2021·Breast Cancer Research : BCR·Toru HanamuraJennifer K Richer
Nov 12, 2021·The Journal of Medical Investigation : JMI·Yoshimi BandoHisanor Uehara
Nov 27, 2021·Essays in Biochemistry·Daniel E FrigoCecilia Williams

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.